Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie
PubMed
27885061
DOI
10.1177/1352458516677589
PII: 1352458516677589
Knihovny.cz E-zdroje
- Klíčová slova
- Alemtuzumab, CD52 antigen, disease-modifying therapy, interferon beta-1a, multiple sclerosis, quality of life,
- MeSH
- alemtuzumab terapeutické užití MeSH
- dospělí MeSH
- imunologické faktory terapeutické užití MeSH
- interferon beta 1a terapeutické užití MeSH
- kvalita života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- relabující-remitující roztroušená skleróza farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- alemtuzumab MeSH
- imunologické faktory MeSH
- interferon beta 1a MeSH
BACKGROUND: Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials. METHODS: Patients who were treatment naive (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36). RESULTS: Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS. CONCLUSION: Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.
Barts and The London School of Medicine and Dentistry Queen Mary University of London London UK
Department of Neurology Hospital Universitario Quirónsalud Madrid Spain
MS Center Department of Neurology 1st Faculty of Medicine Charles University Prague Czech Republic
Multiple Sclerosis Center of Greater Washington Vienna VA USA
Sanofi Genzyme Cambridge MA USA
Virginia Mason Hospital and Seattle Medical Center Seattle WA USA
Citace poskytuje Crossref.org
